Trial of pIL-12/MK-3475 in Metastatic Melanoma

NCT02493361 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Pembrolizumab
DRUG: pIL-12

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]